Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments. One of these, lecanemab ...

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...

Additionally, emerging evidence has linked exercise to improvements in body composition, bone health, sleep quality, pain, chemotherapy-induced peripheral neuropathy, cardiotoxicity, cognitive ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today ...

Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s ...

Cards are now valid for five years instead of two. You can pay and get the card mailed to you through the online portal.

Cantargia (Cantargia AB); (Nasdaq Stockholm:CANTA) today announced new clinical results from two nadunolimab combination therapy trials ...

The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...

A recent study by Dr. Jordan Verplank, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the ...